Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.51 |
| ▸ | MAX | P61244 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22289851 | 0.82 | MAPT (0.74) | MAPTKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL5899116 | 0.80 | CA1 (0.61) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL6815484 | 0.80 | MAPT (0.71) | MAPTKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL22274806 | 0.80 | MAPT (0.71) | MAPTKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL7783081 | 0.80 | MAPT (0.71) | MAPTKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL3297435 | 0.79 | MAPT (0.64) | MAPTKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL3300428 | 0.79 | MYC (0.75) | MAPTKMT2ALMNAMEN1MAPK1 | |
| SCHEMBL6815478 | 0.77 | MAPT (0.77) | MAPTKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL3305182 | 0.76 | NPC1 (0.60) | MAPTKMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL3297371 | 0.76 | MYC (0.70) | MAPTKMT2ALMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | claimed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | claimed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | claimed |
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2010-04-15 | — | — | US | disclosed |
| EP-2074085-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | Lica Pharmaceuticals A/S (DK) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043840-A2 | ANTI-INFECTIVE THIOUREA COMPOUNDS | LICA PHARMACEUTICALS (DK) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093864-A1 | ANTI-INFECTIVE THIOUREA COMPOUNDS | TST, TPX2, TPMT | MAPT 4691/4885KMT2A 1919/4885LMNA 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.